Weiguo Ye - 20 Nov 2023 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Signature
/s/ Ruoyu Chen, as attorney-in-fact for Weiguo Ye
Issuer symbol
GYRE
Transactions as of
20 Nov 2023
Net transactions value
$0
Form type
4
Filing time
22 Nov 2023, 19:49:12 UTC
Previous filing
01 Nov 2023
Next filing
11 Mar 2025

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GYRE Stock Option (Right to Buy) Award $0 +1,665,115 $0.000000 1,665,115 20 Nov 2023 Common Stock 1,665,115 $0.7500 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
F2 These options are vested in full.